stockportfolio.pro
Bio-Rad Laboratories, Inc. (BIO)
Healthcare · Medical Devices · NYSE
Bio-Rad Laboratories, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.07B | $2.16B | $2.29B | $2.31B | $2.55B | $2.92B | $2.80B | $2.67B | $2.57B | $2.58B |
| Gross profit | $1.14B | $1.19B | $1.22B | $1.26B | $1.44B | $1.64B | $1.57B | $1.43B | $1.38B | $1.34B |
| Net income | $26.00M | $122.25M | $365.61M | $1.76B | $3.81B | $4.25B | $-3.63B | $-637.32M | $-1.84B | $759.90M |
| Net margin | 1.3% | 5.7% | 16.0% | 76.1% | 149.8% | 145.6% | -129.5% | -23.9% | -71.9% | 29.4% |
Source: Bio-Rad Laboratories, Inc. SEC filings (10-K). 18 years of history available in the interactive view.
Explore 18 years of Bio-Rad Laboratories, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BIO in your portfolio →
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Bio-Rad Laboratories, Inc. — frequently asked questions
What is Bio-Rad Laboratories, Inc.'s revenue?
Bio-Rad Laboratories, Inc. (BIO) reported revenue of $2.58B for fiscal year 2025, up 0.7% from the prior year, according to its SEC filings.
Is Bio-Rad Laboratories, Inc. profitable?
Yes. BIO earned net income of $759.90M in fiscal 2025, a net margin of 29.4%.
What is BIO's P/E ratio?
Bio-Rad Laboratories, Inc. trades at a price-to-earnings ratio of about 48.8 based on the latest data in our nightly-refreshed cache.
How fast is Bio-Rad Laboratories, Inc. growing?
BIO's revenue grew at roughly 0.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Bio-Rad Laboratories, Inc.'s official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.